First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Nolato AB (publ): the story is balanced — Medical division order intake and backlog growth - new product launches from pharma/medtech customers drive multi-year…
★ Analysts see FY2027 revenue reaching $10.6B — +8.6% growth in a single year.
What Moves the Stock
1Medical division order intake and backlog growth - new product launches from pharma/medtech customers drive multi-year revenue visibility
2Telecom component demand volatility - 5G infrastructure buildout cycles and smartphone production volumes create quarterly earnings swings
3Polymer resin input costs - polypropylene, polyethylene, and engineering plastics represent 30-35% of COGS; price pass-through ability varies by division
4Geographic mix shift - Asia manufacturing (China, Thailand) has lower labor costs but higher logistics/tariff risks; European production serves premium medical customers
5M&A activity - bolt-on acquisitions in medical device manufacturing or vertical integration into drug delivery systems
6Medical Solutions: ~45-50% of revenue - precision polymer components for drug delivery devices, diagnostic equipment, surgical instruments with multi-year customer contracts
7Integrated Solutions: ~30-35% of revenue - telecom/5G infrastructure components, automotive interior parts, EMC shielding for consumer electronics
value - trades at 1.4x P/S and 9.5x EV/EBITDA, below industrial conglomerate peers despite 14.2% ROE and medical exposure.
Rising rates have moderate negative impact through two channels: (1) higher financing costs on working capital (inventory/receivables…
Watch on earnings: Brent crude oil price (BZUSD) - proxy for polymer resin input costs; polypropylene and polyethylene prices correlate 0.7+ with oil, European industrial production index - leading indicator for Integrated Solutions demand from automotive and telecom infrastructure, USD/SEK exchange rate - 40-50% of revenue is USD-denominated (medical exports to US, Asian telecom); SEK strength compresses reported revenue.
One Sentence Summary:
Nolato AB (publ): the story is balanced — medical division order intake and backlog growth - new product launches from pharma/medtech customers drive multi-year revenue visibility.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.